Brent Lucas To Power - 19 Jun 2026 Form 4 Insider Report for Envoy Medical, Inc. (COCH)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: COCH
Reported as of: 19 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 18:28:40 UTC
Prior SEC filing: 04 Jun 2026
Source filing: View source filing
Reporting owner signature: s/ Andrew Nick as Attorney-in-Fact for Brent Lucas pursuant to Power of Attorney previously filed.

Filing notes and source

Key filing fact

Brent Lucas To Power filed Form 4 for Envoy Medical, Inc. (COCH) on 23 Jun 2026.

Key facts

This page summarizes Brent Lucas To Power's Form 4 filing for Envoy Medical, Inc. (COCH).
2 reported transactions and 7 derivative rows are listed below.
Accepted by SEC: 23 Jun 2026, 18:28.

Change

Previous filing in this sequence was filed on 04 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001994382 Primary reporting owner

Lucas Brent T.

Relationship: Chief Executive Officer, Director
Address: C/O 4875 WHITE BEAR PARKWAY, WHITE BEAR LAKE
Signature: s/ Andrew Nick as Attorney-in-Fact for Brent Lucas pursuant to Power of Attorney previously filed.
Signature date: 23 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COCH holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 329,946
Date: 19 Jun 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COCH transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +1,000,000
Change %
Price: $0.000000^*
Shares after: 1,000,000
Date: 19 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 1,000,000
Exercise price: $0.6340
Footnotes: F3

COCH transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +1,000,000
Change %
Price: $0.000000^*
Shares after: 1,000,000
Date: 19 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 1,000,000
Exercise price
Footnotes: F7, F8

COCH holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 879,749
Date: 19 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 879,749
Exercise price: $2.40
Footnotes: F1

COCH holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 200,000
Date: 19 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 200,000
Exercise price: $0.5300
Footnotes: F2

COCH holding Derivative

Warrant (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 110,987
Date: 19 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 110,987
Exercise price: $11.50
Footnotes: F4

COCH holding Derivative

Warrant (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 37,500
Date: 19 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 37,500
Exercise price: $0.4000
Footnotes: F4, F5

COCH holding Derivative

Warrant (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 62,500
Date: 19 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 62,500
Exercise price: $0.4000
Footnotes: F4, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

Footnote F2

Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.

Footnote F3

Options to purchase 250,000 shares vest on 6/19/27, and 750,000 shares vest pro rata on the 19th of each month thereafter for 36 consecutive months.

Footnote F4

Fully exercisable.

Footnote F5

The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.

Footnote F6

The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

Footnote F7

Each restricted stock unit represents a contingent right to receive one share of Envoy Medical, Inc. Class A Common Stock.

Footnote F8

All restricted stock units subject to the RSU Award Grant Notice dated June 19, 2026, will vest as of the date of the official notification by the U.S. Food and Drug Administration (FDA) that it has granted approval (including approval with conditions) for its Acclaim cochlear implant, provided that such announcement occurs during the performance period beginning June 19, 2026 and ending on June 18, 2030.